Fungemia due to Saccharomyces cerevisiae var. boulardii;Fungämie durch Saccharomyces cerevisiae var. boulardii

Chemotherapie Journal

Volumn 17, Issue 2, 2008, Pages 57-61

  Trautmann, Matthias ^a   Synowzik, Iris ^a   Nadji Ohl, Minou ^a   Von Voigt, Tatjana Beyer ^b   Reiter, W ^b  

^a KLINIKUM STUTTGART   (Germany)

^b KATHARINENHOSPITAL   (Germany)

Author keywords

Fungemia; Saccharomyces boulardii; Saccharomyces cerevisiae

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN; VORICONAZOLE;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CENTRAL VENOUS CATHETER; CLINICAL FEATURE; CONTAMINATION; CRITICALLY ILL PATIENT; DRUG EFFECT; DRUG EFFICACY; FUNGEMIA; FUNGUS IDENTIFICATION; HEALTH CARE PERSONNEL; HUMAN; INTENSIVE CARE UNIT; RISK FACTOR; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE; STOMACH TUBE; SYMPTOM; YEAST CELL;

EID: 42149153888     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Burkhardt O, Kohnlein T, Pletz M, Welte T. Saccharomyces boulardii induced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand J Infect Dis 2005;37:69-72.
2. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutrition 2006;83:1256-64.
3. Can M, Besirbellioglu BA, Avci IY, et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit 2006;12:19-22.
4. Cassone M, et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighbouring those treated with a probiotic preparation of the organism. J Clin Microbiol 2003;41:5340-3.
5. Coignard B, Barbut F, Blanckaert K, et al. Emergence of Clostridium difficile toxinotype III, PCR-ribotype 027-associated disease, France, 2006. Eurosurveillance 2006;11:E060914.1.
6. de Llanos R, et al. A comparison of clinical and food Saccharomyces cerevisiae isolates on the basis of potential virulence factors. Antonie Van Leeuwenhoek 2006;90:221-31.
7. Edwards-Ingram L, et al. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol 2007;73:2458-67.
8. Hennequin C, Kauffmann-LaCroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000;19:16-20.
9. Herbrecht R, Nivoix Y. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis 2005;40:1635-7.
10. Johnston BC, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2007 (April 18) CD 004827.
11. Katz JA. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. J Clin Gastroenterol 2006;40:249-55.
12. Kuijper EJ, van den Berg RJ, Debast S, et al. Clostridium difficile ribotype 027, toxinotype III, in the Netherlands. Emerg Infect Dis 2006;12:827-30.
13. Lestin F, Pertschy A, Rimek D. Fungämie nach oraler Behandlung mit Saccharomyces boulardii bei einem Patienten mit multiplen Begleiterkrankungen. Dtsch Med Wochenschr 2003;128:2531-3.
14. Loo VG, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
15. Madsen KL. The use of probiotics in gastrointestinal diseases. Can J Gastroenterol 2001;15:817-22.
16. McDonald LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
17. McFarland LV, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8.
18. McFarland LV. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007;5:97-105.
19. Munoz P, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625-34.
20. Pothoulakis C, Kelly JP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993;104:1108-15.
21. Reichardt C, Chaberny IF, Kola A, et al. Dramatischer Anstieg von Clostridium difficile-assoziierter Diarrhö in Deutschland: Ist der neue Stamm PCR-Ribotyp 027 bereits angekommen? Dtsch Med Wochenschr 2007;132:223-8.
22. Rusek R, et al. Clostridium difficile surveillance in London, England. Abstract no. P17.69. J Hosp Infect 2006;64(Suppl 1):S103.
23. Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in the prevention of acute diarrhoea: a meta-analysis of masked, randomized, placebo-controlled trials. Lancet Infect Dis 2006;6:374-82.
24. Schneider T, Eckmanns T, Ignatius R, et al. Clostridium difficile assoziierte Diarrhö. Ein zunehmendes klinisches Problem durch neue hochvirulente Erreger. Dtsch Arztebl 2007;104:A1588-94.
25. Surawicz CM, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-7.
26. Szajewska H, et al. Meta-Analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007;25:257-64.
27. Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006;149:367-72.
28. van der Aa Kühle A, Jespersen L. The taxonomic position of Saccharomyces boulardii as evaluated by sequence analysis of the D1/D2 domain of 26S rDNA, the ITS1-5.8S rDNA-LTS2 region and the mitochondrial cytochrome-c oxidase II gene. Syst Appl Microbiol 2003;26:564-71.
29. Volkheimer G, et al. On resorption and excretion of intact yeast cells. Zentrabl Bakteriol [Orig] 1964;192:121-5.